Latest Veridex LLC Stories
RARITAN, N.J., July 13 /PRNewswire/ -- Measuring the change in circulating tumor cell (CTC) count can accurately predict the prognosis and survival in patients with metastatic breast cancer (MBC), according to a newly published report in the July 10 issue of the Journal of Clinical Oncology.
Proprietary Veridex Technology is the First Cancer Diagnostic Test to Automate and Capture Circulating Tumor Cells RARITAN, N.J., May 7 /PRNewswire/ -- Veridex, LLC announced today that the CellSearch(R) System to measure circulating tumor cells (CTCs) will be offered at Florida Cancer Specialists (FCS), the largest privately-owned oncology and hematology practice in Florida.
RARITAN, N.J., Nov. 12 /PRNewswire/ -- Veridex, LLC announced today that the technology used in the CellSearch(R) System to measure circulating tumor cells (CTCs) was ranked as the top medical innovation for 2009 by the Cleveland Clinic, a leading multispecialty academic medical center.
Immunicon Corporation (OTCBB:IMMC.OB) announced today that Immunicon Corporation and its wholly-owned subsidiaries completed their previously announced sale of substantially all of their assets to Veridex, LLC ("Veridex") in a sale conducted under the provisions of Section 363 of the U.S.
RARITAN, N.J., Aug. 1 /PRNewswire/ -- Veridex, LLC announced today it has completed its previously announced acquisition of substantially all of the assets of Immunicon Corporation (BULLETIN BOARD: IMMC) and its wholly-owned subsidiaries.
RARITAN, N.J., July 25 /PRNewswire/ -- An international, prospective clinical trial found the number of circulating tumor cells (CTCs) is a strong indicator of progression-free and overall survival among metastatic colorectal cancer patients, according to a report published in the July 1 issue of the Journal of Clinical Oncology.
Research and Markets Laura Wood, Senior Manager Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 firstname.lastname@example.org Logo: http://www.researchandmarkets.com Research and Markets (http://www.researchandmarkets.com/research/ 8d3dd7/commercializing_mo) has announced the addition of the "Commercializing Molecular Diagnostics: Products, Services, Companies and Global Market" report to their offering.